Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Paul E. Sax(Brigham and Women's Hospital), David A. Wohl(University of North Carolina at Chapel Hill), Adriano Lazzarin(Vita-Salute San Raffaele University), Hailin Huang(University of Electronic Science and Technology of China), José Ramón Arribas(Hospital Universitario La Paz), Anton Pozniak, Jared M. Baeten(University of Washington), Yazdan Yazdanpanah(Inserm), Rima Acosta(Gilead Sciences (United States)), Franco Maggiolo(Ospedale Papa Giovanni XXIII), Jason T. Hindman(Gilead Sciences (United States)), Hal D. Martin(Gilead Sciences (United States)), Edwin DeJesus(Orlando Immunology Center), Hans‐Jürgen Stellbrink, Chloe Orkin(Queen Mary University of London)
Cited by 90
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
|The Lancet|2010|958
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886